Deconsolidation in Medical Devices
The medical device/diagnostic industry has been a hotbed of merger and acquisition activity over the past five years, mostly driven by large companies. But by at least one measure, the industry is actually deconsolidating, according to data developed by The Wilkerson Group/IBM.
You may also be interested in...
The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.